Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03858972
Title Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC (CONTESSA 2)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Odonate Therapeutics, Inc.

Her2-receptor negative breast cancer


Capecitabine + Tesetaxel

Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.